CRISPR Therapeutics AG’s filing revealed that its Chief Financial Officer Prasad Raju unloaded Company’s shares for reported $1.79 million on Jan 06 ’26. In the deal valued at $60.16 per share,29,700 shares were sold. As a result of this transaction, Prasad Raju now holds 6,767 shares worth roughly $0.36 million.
Then, RAJU PRASAD bought 29,700 shares, generating $1,786,636 in total proceeds.
Before that, Prasad Raju sold 10,000 shares. CRISPR Therapeutics AG shares valued at $559,549 were divested by the Chief Financial Officer at a price of $55.95 per share. As a result of the transaction, Prasad Raju now holds 6,767 shares, worth roughly $0.36 million.
JP Morgan initiated its CRISPR Therapeutics AG [CRSP] rating to an Overweight in a research note published on September 18, 2025; the price target was $70. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who increased its forecast for the stock in mid February from “an In-line” to “an Outperform”. TD Cowen also remained covering CRSP and has increased its forecast on February 12, 2025 with a “Hold” recommendation from previously “Sell” rating. H.C. Wainwright started covering the stock on February 03, 2025. It rated CRSP as “a Buy”.
Price Performance Review of CRSP
On Monday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock fall -4.54% to $53.84. Over the last five days, the stock has gained 0.13%. CRISPR Therapeutics AG shares have risen nearly 28.44% since the year began. Nevertheless, the stocks have risen 2.67% over the past one year.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on 2025-12-15, dropping by -1.32 million shares to a total of 21.86 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 23.19 million shares. There was a decline of -6.05%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 06, 2024 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $84.
